Quince Therapeutics, Inc.
QNCXNASDAQHealthcareBiotechnology
Previous close
$33.93
+$1.82 · +5.67%
QNCX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Momentum
17
Strong Down
Sentiment
56
Mixed
Risk resilience
28
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteQuince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Dirk Thye
- Listed since
- May 9, 2019
- Employees
- 38
Market position
Day range
Current $33.93
52-week range
Current $33.93
- Open
- $33.19
- Previous close
- $32.11
- Volume
- 9.54K
- 0.17× average
- Average volume
- 56.48K
- Average daily volume
- Market cap
- 9.45M USD
- Beta
- 1.4
- Market reference 1
- 50-day average
- $22.4844
- +50.90% above average
- 200-day average
- $190.47
- -82.19% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 180.49M USD
- P/E (TTM)
- -0.49×
- P/B (TTM)
- -5.89×
- P/S (TTM)
- 0×
- EV / EBITDA
- -2.24×
- Earnings yield
- -50.04%
- Free cash flow yield
- -24.89%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- 235.14%
- Return on assets
- -89.80%
- Return on invested capital
- -73.69%
Financial health
- Debt / equity
- 0×
- Current ratio
- 0.53×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 142K USD | — | — | — | — |
| Gross profit | −142K USD | — | — | — | — |
| Research and development | 35.38M USD | 18.59M USD | 9.45M USD | 25.18M USD | 60.8M USD |
| Selling, general, and administrative | 15.05M USD | 17.58M USD | 17.7M USD | 26.01M USD | 29.52M USD |
| Operating expenses | 50.29M USD | 57.29M USD | 34.62M USD | 52.02M USD | 90.32M USD |
| Interest income | 1.24M USD | 2.93M USD | 3.48M USD | 1.07M USD | 620K USD |
| Interest expense | — | — | — | 568K USD | — |
| Depreciation and amortization | 142K USD | 186K USD | 322K USD | 204K USD | 344K USD |
| Operating income | −50.43M USD | −57.29M USD | −34.62M USD | −52.02M USD | −90.32M USD |
| Net income | −83.98M USD | −56.83M USD | −31.39M USD | −51.66M USD | −89.95M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 50%
- 4 beats, 4 misses, 0 met estimates
- Average EPS surprise
- +42.37%
- 8 comparable reports
- Latest EPS result
- -12.31
- Estimate -28.02 · Beat by 56.07%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$69.00
103.36% upsidePrice history unavailable
High $70.00Average $69.00Low $68.00Rating distribution
11 ratingsQNCX news
QNCX peers
Continue in GoAI
Research QNCXresearch.disclaimer